Vanilic acid derivative containing thiosemicarbazide structure and application of vanillic acid derivative
By developing vanillic acid derivatives containing an aminothiourea structure, the shortcomings of existing antioxidants and α-glucosidase inhibitors have been addressed, achieving more efficient antioxidant and α-glucosidase inhibition effects, and providing better means to treat type 2 diabetes and improve overall health.
Patent Information
- Application Number
- CN202511157308.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-08-19
- Publication Date
- 2025-11-28
AI Technical Summary
Existing alpha-glucosidase inhibitors such as acarbose and voglibose have limited efficacy and significant side effects in treating type 2 diabetes. Meanwhile, existing antioxidants such as vanillic acid, vitamin C, and vitamin E are not very effective in scavenging free radicals.
A vanillic acid derivative containing an aminothiourea structure was developed, specifically 2-(4-(benzyloxy)-3-methoxybenzoyl)-N-isopropylhydrazine-1-methylthioamide, to enhance antioxidant capacity and inhibit α-glucosidase activity. Its scavenging activity against DPPH and ABTS and its inhibitory activity against α-glucosidase were determined.
This compound exhibits superior antioxidant activity compared to vanillic acid, vitamin C, and vitamin E, with an IC50 value of 5.33–13.46 μg/mL. It also demonstrates superior inhibitory effects on α-glucosidase compared to vanillic acid and acarbose, with an IC50 value of 34.99 μg/mL, indicating higher efficacy and fewer side effects.
Smart Images

Figure CN121021356A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of pharmaceutical technology, specifically to a vanillic acid derivative containing an aminothiourea structure, and also to the application of this vanillic acid derivative containing an aminothiourea structure in terms of anti-oxidation and anti-α-glucosidase. Background Technology
[0002] The human body is equipped with a complex enzymatic and non-enzymatic antioxidant defense system that effectively counteracts the harmful effects of free radicals and other oxidizing substances. Free radicals are linked to the progression of various health conditions, such as cancer, heart disease, neurodegenerative diseases, and Alzheimer's disease. Increasing the consumption of antioxidants through diet can enhance the body's defense against these harmful substances. Numerous studies have shown that foods rich in antioxidants, especially those containing essential antioxidant nutrients, are crucial for disease prevention; furthermore, a growing consensus among scientists is that antioxidants can improve overall health by slowing or preventing the development of degenerative diseases and age-related illnesses.
[0003] Diabetes, especially type 2 diabetes, is characterized by insufficient insulin secretion and reduced insulin activity, leading to disorders of carbohydrate, protein, and fat metabolism. It has become a global epidemic, affecting more than 350 million people worldwide and is considered a leading cause of death. Treatment for type 2 diabetes involves a variety of approaches, including stimulating endogenous insulin secretion, reducing insulin requirements, and inhibiting carbohydrate digestion. Alpha-glucosidase inhibitors are an important class of drugs for treating type 2 diabetes. Common alpha-glucosidase inhibitors, such as acarbose, miglitol, and voglibose, are widely used in clinical practice to delay carbohydrate digestion, thereby reducing postprandial blood glucose spikes and improving blood glucose levels. Developing novel alpha-glucosidase inhibitors with higher efficacy and fewer side effects is an ongoing research direction in the field of medicinal chemistry. Summary of the Invention
[0004] The purpose of this invention is to provide a vanillic acid derivative containing an aminothiourea structure that has good antioxidant and anti-α-glucosidase activity.
[0005] A vanillic acid derivative containing an aminothiourea structure according to the present invention has the following general formula:
[0006]
[0007] In formula (I): R1 is selected from substituents such as hydrogen and fluorine; R2 is selected from substituents such as methyl, ethyl, propyl, isopropyl, and phenyl.
[0008] The specific compound is:
[0009] Compound 5a: 2-(4-(benzyloxy)-3-methoxybenzoyl)-N-methylhydrazine-1-methylthioamide;
[0010] Compound 5b: 2-(4-(benzyloxy)-3-methoxybenzoyl)-N-ethylhydrazine-1-methylthioamide;
[0011] Compound 5c: 2-(4-(benzyloxy)-3-methoxybenzoyl)-N-propylhydrazine-1-methylthioamide;
[0012] Compound 5d: 2-(4-(benzyloxy)-3-methoxybenzoyl)-N-isopropylhydrazine-1-methylthioamide;
[0013] Compound 5e: 2-(4-(benzyloxy)-3-methoxybenzoyl)-N-phenylhydrazine-1-methylthioamide;
[0014] Compound 5f: 2-(4-(4-fluorobenzyloxy)-3-methoxybenzoyl)-N-methylhydrazine-1-methylthioamide;
[0015] Compound 5g: 2-(4-(4-fluorobenzyloxy)-3-methoxybenzoyl)-N-ethylhydrazine-1-methylthioamide;
[0016] Compound 5h: 2-(4-(4-fluorobenzyloxy)-3-methoxybenzoyl)-N-propylhydrazine-1-methylthioamide;
[0017] Compound 5i: 2-(4-(4-fluorobenzyloxy)-3-methoxybenzoyl)-N-isopropylhydrazine-1-methylthioamide;
[0018] Compound 5j: 2-(4-(4-fluorobenzyloxy)-3-methoxybenzoyl)-N-phenylhydrazine-1-methylthioamide.
[0019] Application of a vanillic acid derivative containing an aminothiourea structure in antioxidant applications, wherein the IC50 of the compound's scavenging activity against DPPH and ABTS is [not specified in the original text]. 50 The values ranged from 5.33 to 35.83 and from 5.84 to 13.46 μg / mL, respectively, with some compounds showing superior performance compared to the control agents vanillic acid, vitamin C, and vitamin E. Among these, compound 2-(4-(benzyloxy)-3-methoxybenzoyl)-N-isopropylhydrazine-1-methylthioyl showed the best IC50 values for DPPH and ABTS scavenging activity. 50 The values were 5.33 and 5.84 μg / mL, respectively, with the best results.
[0020] The application of vanillic acid derivatives containing an aminothiourea structure in the inhibition of α-glucosidase: at a concentration of 200 μg / mL, the inhibitory activity of these compounds against α-glucosidase ranges from 15.94% to 90.31%, with some compounds showing superior activity compared to the control agents vanillic acid and acarbose; the IC50 of the compound 2-(4-(benzyloxy)-3-methoxybenzoyl)-N-isopropylhydrazine-1-methylthioyl against α-glucosidase is [not specified in the original text]. 50 The value was 34.99 μg / mL, indicating the best effect. Detailed Implementation
[0021] Example 1: Determination of the scavenging activity of the target compound against DPPH and ABTS
[0022] DPPH scavenging activity assay: 5 mg of the target compound was dissolved in 100 mL of methanol to prepare a stock solution with a concentration of 50 μg / mL. Then, 160 μL of the stock solution and 40 μL of 0.5 μM DPPH solution were added to a 96-well plate to obtain a reaction mixture with a concentration of 40 μg / mL. After reacting in the dark for 30 min, the absorbance value was measured at 517 nm using a full-wavelength multi-mode microplate reader. Dimethyl sulfoxide was used as a negative control, and vanillic acid and vitamin C were used as positive controls.
[0023] ABTS scavenging activity assay: 0.2 mL of 2.6 mM K2S2O8 solution and 0.2 mL of 7.4 mM ABTS solution were mixed and reacted in the dark at room temperature for 12 h. The mixture was then diluted 50 times with pH 7.4 PBS buffer. 6.25 mg of the target compound was dissolved in 100 mL of methanol to obtain a stock solution with a concentration of 62.5 μg / mL. Subsequently, 160 μL of the stock solution and 40 μL of ABTS solution were added to a 96-well plate to obtain a reaction mixture with a concentration of 50 μg / mL. After reacting in the dark for 30 min, the absorbance was measured at 734 nm using a multi-wavelength microplate reader. Dimethyl sulfoxide was used as a negative control, and vanillic acid and vitamin E were used as positive controls.
[0024] The formulas for calculating the scavenging activity of the target compound against DPPH and ABTS are as follows:
[0025] Scavenging activity (%) = (OD value of control group - OD value of treatment group) / OD value of control group × 100%;
[0026] The scavenging activity and IC50 of the target compound were determined using the methods described above. 50 The values are shown in Table 1.
[0027] Table 1. DPPH scavenging activity of the target compounds
[0028]
[0029]
[0030] Table 1 shows that the IC50 values of the target compound for scavenging DPPH and ABTS are: 50 The values ranged from 5.33 to 35.83 and from 5.84 to 13.46 μg / mL, respectively, with some compounds showing superior performance compared to the control agents vanillic acid, vitamin C, and vitamin E. Among them, compound 2-(4-(benzyloxy)-3-methoxybenzoyl)-N-isopropylhydrazine-1-methylthioyl (5d) exhibited better IC50 values for DPPH and ABTS scavenging activities. 50 The values were 5.33 and 5.84 μg / mL, respectively, showing the best effect and being superior to the control drugs vanillic acid, vitamin C, and vitamin E.
[0031] Example 2: Assay of the anti-α-glucosidase activity of the target compound
[0032] 4 mg of the target compound was dissolved in 100 μL of dimethyl sulfoxide and 900 μL of pH 6.8 PBS buffer to prepare a stock solution with a concentration of 400 μg / mL. Then, 20 μL of α-glucosidase (final concentration 0.5 U / mL), 70 μL of PBS buffer, 80 μL of 0.2 M sodium carbonate solution, and 10 μL of the test compound stock solution were added sequentially to a 96-well plate. After reacting at 37 °C for 10 min, 20 μL of p-nitrobenzene-β-D-glucopyranoside (final concentration 2.5 mM) was added, and after reacting at 37 °C for 30 min, the absorbance was measured at 405 nm using a multi-wavelength microplate reader. Dimethyl sulfoxide was used as a negative control, and vanillic acid and acarbose were used as positive controls.
[0033] The formula for calculating the anti-α-glucosidase activity of the target compound is as follows:
[0034] Anti-α-glucosidase activity (%) = (OD value of control group - OD value of treatment group) / OD value of control group × 100%;
[0035] The inhibitory activity and IC50 of the target compound were determined using the methods described above. 50 The values are shown in Table 2.
[0036] Table 2 Anti-α-glucosidase activity of target compounds
[0037]
[0038]
[0039] Table 2 shows that at a concentration of 200 μg / mL, the inhibitory activity of these compounds against α-glucosidase ranged from 15.94% to 90.31%, with some compounds showing superior activity compared to the control agents vanillic acid and acarbose. Among them, compound 2-(4-(benzyloxy)-3-methoxybenzoyl)-N-isopropylhydrazine-1-methylthioyl (5d) exhibited the best inhibitory activity against α-glucosidase, with an IC50 value of [missing information]. 50 The value was 34.99 μg / mL, which showed the best effect and was superior to the control drugs vanillic acid and acarbose.
Claims
1. A vanillic acid derivative containing an aminothiourea structure, characterized in that, Its derivatives have the following general formula: In formula (I): R1 is selected from substituents such as hydrogen and fluorine; R2 is selected from substituents such as methyl, ethyl, propyl, isopropyl, and phenyl. The specific compound is: Compound 5a: 2-(4-(benzyloxy)-3-methoxybenzoyl)-N-methylhydrazine-1-methylthioamide; Compound 5b: 2-(4-(benzyloxy)-3-methoxybenzoyl)-N-ethylhydrazine-1-methylthioamide; Compound 5c: 2-(4-(benzyloxy)-3-methoxybenzoyl)-N-propylhydrazine-1-methylthioamide; Compound 5d: 2-(4-(benzyloxy)-3-methoxybenzoyl)-N-isopropylhydrazine-1-methylthioamide; Compound 5e: 2-(4-(benzyloxy)-3-methoxybenzoyl)-N-phenylhydrazine-1-methylthioamide; Compound 5f: 2-(4-(4-fluorobenzyloxy)-3-methoxybenzoyl)-N-methylhydrazine-1-methylthioamide; Compound 5g: 2-(4-(4-fluorobenzyloxy)-3-methoxybenzoyl)-N-ethylhydrazine-1-methylthioamide; Compound 5h: 2-(4-(4-fluorobenzyloxy)-3-methoxybenzoyl)-N-propylhydrazine-1-methylthioamide; Compound 5i: 2-(4-(4-fluorobenzyloxy)-3-methoxybenzoyl)-N-isopropylhydrazine-1-methylthioamide; Compound 5j: 2-(4-(4-fluorobenzyloxy)-3-methoxybenzoyl)-N-phenylhydrazine-1-methylthioamide.
2. The application of the vanillic acid derivative with an aminothiourea structure as described in claim 1 in terms of antioxidant properties.
3. The application of a vanillic acid derivative with an aminothiourea structure as described in claim 1 in the treatment of α-glucosidase.
4. The application of the vanillic acid derivative with an aminothiourea structure as described in claim 2 in antioxidant properties, characterized in that, The antioxidant application is the scavenging activity against DPPH and ABTS.
5. The application of a vanillic acid derivative with an aminothiourea structure as described in claim 4 in antioxidant properties, characterized in that, The IC50 of the compound's scavenging activity against DPPH and ABTS 50 The values ranged from 5.33 to 35.83 and from 5.84 to 13.46 μg / mL, respectively. Some compounds were superior to the control agents vanillic acid, vitamin C, and vitamin E. Among them, the IC50 values of compound 2-(4-(benzyloxy)-3-methoxybenzoyl)-N-isopropylhydrazine-1-methylthioyl showed the best DPPH and ABTS scavenging activity. 50 The values were 5.33 and 5.84 μg / mL, respectively, with the best results.
6. The application of a vanillic acid derivative with an aminothiourea structure as described in claim 3 in its anti-α-glucosidase activity, characterized in that, At a concentration of 200 μg / mL, the inhibitory activity of these compounds against α-glucosidase ranged from 15.94% to 90.31%, with some compounds showing superior activity compared to the control agents vanillic acid and acarbose. Among these, the IC50 of compound 2-(4-(benzyloxy)-3-methoxybenzoyl)-N-isopropylhydrazine-1-methylthioyl against α-glucosidase was [not specified in the original text]. 50 The value was 34.99 μg / mL, indicating the best effect.
